Protocol Summaries: GSK2132231
| GSK Study ID |
Phase | Title | Status |
|---|---|---|---|
| 111476 | Phase 2 | GSK2132231A Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with unresectable metastatic melanoma | Recruiting |
| 111482 | Phase 3 | GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma | Recruiting |
| 111714 | Phase 1 | Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in association with chemotherapy in patients with unresectable and progressive metastatic cutaneous melanoma | Recruiting |